REVUFORJ

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Nov 15, 2024

   1 yr 7 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Nov 15, 2029

   in 3 yr 6 mo

4. Exclusivity ends · ODE-502

   Orphan-drug exclusivity (7 years)

   Nov 15, 2031

   in 5 yr 6 mo

5. Exclusivity ends · ODE-504

   Orphan-drug exclusivity (7 years)

   Nov 15, 2031

   in 5 yr 6 mo

6. Exclusivity ends · ODE-505

   Orphan-drug exclusivity (7 years)

   Nov 15, 2031

   in 5 yr 6 mo

7. Patent 10683302 expires

   Listed drug substance patent expiration.

   Jun 08, 2037

   in 11 yr 2 mo

8. Patent 11479557 expires

   Listed drug product patent expiration.

   Jun 08, 2037

   in 11 yr 2 mo

9. Patent 11479557 expires

   Listed drug product patent expiration.

   Jun 08, 2037

   in 11 yr 2 mo

10. Patent 12564590 expires

    Listed drug product patent expiration.

    Dec 18, 2042

    in 16 yr 9 mo

11. Patent 12564590 expires

    Listed drug product patent expiration.

    Dec 18, 2042

    in 16 yr 9 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (4)

• NCENew chemical entity exclusivity (5 years)

  Nov 15, 2029

  in 3 yr 6 mo

• ODE-502Orphan-drug exclusivity (7 years)

  Nov 15, 2031

  in 5 yr 6 mo

• ODE-504Orphan-drug exclusivity (7 years)

  Nov 15, 2031

  in 5 yr 6 mo

• ODE-505Orphan-drug exclusivity (7 years)

  Nov 15, 2031

  in 5 yr 6 mo

Listed patents (5)